See this page online at: http://www.biotechfocus.com/2008Issue7
Sign up for your free subscription and keep up-to-date.
Stay updated on the latest news and technologies with Bioscienceworld's newsletters.
Five to choose from.
|
Outsourcing Early Stage Drug Development To China The Great Debate
By Shawn Lawrence
Outsourcing pieces of drug discovery has become a common cost-cutting measure in the biotechnology industry. |
|
Bioprocessing, Microorganisms and Enzymes: From Discovery To Industrial Translation
By Denis Groleau
Converting promising discoveries into commercial products and processes (industrial translation) is very risky, difficult, costly and time-consuming. In recent years, this has been recognized as one of Canada’s main weaknesses in the high tech area, especially in biotechnology. Moving from discovery to industrial translation represents a continuum of activities. Nevertheless, these activities may be separated into three major blocks: Discovery; Development; and Commercial production. Bioprocessing can contribute to each one of these three blocks of activities but its importance naturally increases along the commercialization chain. At NRC-BRI, the Microbial and Enzymatic Technology Group has contributed to the three areas. |
|
Listings
Listings by Category.
|